Show Summary Details
Page of

Secondary Liver Tumors 

Secondary Liver Tumors
Secondary Liver Tumors

Samuel L. Rice

, David C. Madoff

, and Stephen B. Solomon

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 October 2019

Metastatic spread of primary neoplasms to the liver is a poor prognostic factor in oncology. It is associated with a diminished overall survival (OS) rate, with most patients living only 1–2 years after tumors are identified. Systemic chemotherapy is the mainstay of treatment for patients with secondary tumors to the liver. An urgent need exists for the development and utilization of novel therapies to improve survival in these patients. Minimally invasive therapies exist that target hepatic tumors and can work synergistically with the systemic treatments currently available to prolong survival. Interventional radiologists have developed and utilized various liver-directed therapies, including embolization and ablation, to improve patient survival. Given the data that is available, these treatments are underutilized by clinicians due to a lack of knowledge about the potential advantages. This chapter discusses the factors related to treating secondary neoplasms in the liver and reviews the evidence supporting these therapies.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.